CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis.
Total raised: $40M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2024 | Series B | $40M | - |
Mentions in press and media 2
| Date | Title | Description |
| 16.05.2024 | CinDome Pharma Raises $40M in Series B Extension | CinDome Pharma, a Cincinnati, OH-based company dedicated to advancing a safe, chronic therapy for gastroparesis, raised $40M in Series B extension funding. The round, which brought the total amount to $59M, included participation from Perce... |
| - | CinDome Pharma | “CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis.” |